Award
National Cancer Institute 2R01CA190394-11A1
Targeting the cytokine circuitry of KRAS driven lung cancer
Recipient
National Cancer Institute (NCI), part of the National Institutes of Health (NIH)
Award Amount
$460,600.00
Ceiling
$460,600.00
Awarded
April 06, 2026
Identifier
2R01CA190394-11A1
This award funds research on KRAS driven lung cancer, aiming to understand and target immune vulnerabilities in cancer cells to develop potential clinical therapies.
Description
The project focuses on studying the cells that survive KRAS targeted therapy and exposing their vulnerability to the immune system. The work has potential for translation into clinical trials for KRAS mutant lung cancer. The project involves studying immune signaling pathways, tumor heterogeneity, and potential therapeutic targets such as TREX1 and PARP7.